Gliris 3 Tablet contains Glimepiride 3 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from pancreatic beta cells, thereby improving glycemic control in patients with insufficient endogenous insulin production. Glimepiride enhances peripheral tissue sensitivity to insulin, contributing to better glucose utilization and reduced blood glucose levels. This medication is typically prescribed as an adjunct to diet and exercise to achieve optimal glycemic control in adults with non-insulin-dependent diabetes. Gliris 3 Tablet should be administered once daily with breakfast or the first main meal to minimize the risk of hypoglycemia. Dose adjustments may be necessary based on individual patient response and glycemic targets. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Patient education on recognizing and managing hypoglycemia is essential to ensure safe and effective use of Gliris 3 Tablet.

Dosage & How to Use